乾癬市場：ヨーロッパ主要国の治療薬市場...市場調査レポートについてご紹介

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Leading Prescribed Drugs and Treatment Guidelines
4.1.3 Clinical Practice
4.2 5EU
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles – Major Brands
5.3.1 Enbrel (Etanercept)
5.3.2 Humira (Adalimumab)
5.3.3 Remicade (Infliximab)
5.3.4 Stelara (ustekinumab)
5.3.5 Cosentyx (Secukinumab)
5.3.6 Otezla (Apremilast)
5.3.7 Taclonex and Enstilar (Calcipotriene and Betamethasone Dipropionate)
5.3.8 Methotrexate
5.3.9 Fumaderm (Fumaric Acid Esters)
5.3.10 Alzumab (itolizumab)
5.3.11 Other Therapeutic Drug Classes Used in Psoriasis
5.3.12 Non-pharmacological Therapy
6 Unmet Need and Opportunity
6.1 Overview
6.2 Limited Patient Access Due to Drug Reimbursement Pattern
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Improved Drug Safety and Efficacy Profiles
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Education and Treatment of Psychological Factors Accompanying Psoriasis
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Clinical Trial Mapping
7.2.1 Clinical Trials by Country
7.3 Clinical Trials by Phase and Trial Status
7.4 Promising Drugs in Clinical Development
7.4.1 Xeljanz (Tofacitinib)
7.4.2 Ixekizumab (LY2439821)
7.4.3 Brodalumab
7.4.4 Guselkumab (CNTO-1959)
7.4.5 Tildrakizumab
7.4.6 Piclidenoson (CF-101)
7.4.7 Additional Phase III Pipeline Products
7.4.8 Phase II Pipeline Products
7.4.9 Phase I Pipeline Products
7.5 Biosimilar Pipeline Products
7.5.1 Introduction
7.5.2 Hospira’s Inflectra Versus J&J’s Remicade in Key Autoimmune Diseases
7.5.3 Biosimilars in the Immunology Community
7.5.4 By the Numbers: Biosimilars in Development
7.5.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry
7.5.6 Uptake of Biosimilars for Psoriasis is Expected to Vary by Market
7.5.7 Biosimilars Forecast
8 Market Outlook
8.1 5EU
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Psoriasis Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline agents
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research – Prescriber Survey
9.7 About the Authors
9.7.1 Author
9.7.2 Reviewer
9.7.3 Epidemiologist
9.7.4 Global Director of Therapy Analysis and Epidemiology
9.7.5 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer